Biomea Fusion, Inc. Proceeds from (Repayments of) Notes Payable
Biomea Fusion, Inc. (BMEA) reported Proceeds from (Repayments of) Notes Payable of -$36.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2024-03-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfNotesPayable · last filed 2024-03-28
- Biomea Fusion, Inc. proceeds from (repayments of) notes payable for the quarter ending 2021-12-31 was $0.00.
- Biomea Fusion, Inc. proceeds from (repayments of) notes payable for the quarter ending 2021-09-30 was $0.00.
- Biomea Fusion, Inc. proceeds from (repayments of) notes payable for the quarter ending 2020-12-31 was $0.00.
- Biomea Fusion, Inc. proceeds from (repayments of) notes payable for the quarter ending 2020-09-30 was $0.00.
- Biomea Fusion, Inc. proceeds from (repayments of) notes payable for fiscal 2021 was -$36.00K, a 200.00% decline from fiscal 2020.
- Biomea Fusion, Inc. proceeds from (repayments of) notes payable for fiscal 2020 was $36.00K.
| Period end | Proceeds from (Repayments of) Notes Payable 3 month | Proceeds from (Repayments of) Notes Payable 6 month | Proceeds from (Repayments of) Notes Payable 9 month | Proceeds from (Repayments of) Notes Payable 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | -$36.00K 10-K · filed 2024-03-28 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$36.00K 10-Q · filed 2021-11-03 | ||
| 2021-06-30 | -$36.00K 10-Q · filed 2021-08-11 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $0.00 derived: sum of 2 quarters · filed 2023-03-28 | $36.00K 10-K · filed 2023-03-28 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $36.00K 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | $36.00K 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |